Pelvic sentinel lymph node biopsy in endometrial cancer-a simplified algorithm based on histology and lymphatic anatomy.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
03 2020
Historique:
received: 17 09 2019
revised: 07 12 2019
accepted: 26 12 2019
pubmed: 23 2 2020
medline: 25 8 2020
entrez: 21 2 2020
Statut: ppublish

Résumé

To achieve the full potential of sentinel lymph node (SLN) detection in endometrial cancer, both presumed low- and high-risk groups should be included. Perioperative resource use and complications should be minimized. Knowledge on distribution and common anatomical sites for metastatic SLNs may contribute to optimizing the concept while maintaining sensitivity. Proceeding from previous studies, simplified algorithms based on histology and lymphatic anatomy are proposed. Data on mapping rates and locations of pelvic SLNs (metastatic and non-metastatic) from two previous prospective SLN studies in women with endometrial cancer were retrieved. Cervically injected indocyanine green was used as a tracer and an ipsilateral re-injection was performed in case of non-display of the upper and/or lower paracervical pathways. A systematic surgical algorithm was followed with clearly defined SLNs depicted on an anatomical chart. In high-risk endometrial cancer patients, removal of SLNs was followed by a pelvic and para-aortic lymphadenectomy. 423 study records were analyzed. The bilateral mapping rates of the upper and lower paracervical pathways were 88.9% and 39.7%, respectively. 72% of all SLNs were typically positioned along the upper paracervical pathway (interiliac and/or proximal obturator fossa) and 71 of 75 (94.6%) of pelvic node positive women had at least one metastatic SLN at either of these positions. Women with grade 1-2 endometroid cancers (n=275) had no isolated metastases along the lower paracervical pathway compared with two women with high-risk histologies (n=148). SLNs along the upper paracervical pathway should be identified in all endometrial cancer histological subtypes; removal of nodes at defined typical positions along the upper paracervical pathway may replace a site-specific lymphadenectomy in case of non-mapping despite tracer re-injection. Detection of SLNs along the lower paracervical pathway can be restricted to high-risk histologies and a full pre-sacral lymphadenectomy should be performed in case of non-display.

Identifiants

pubmed: 32075897
pii: ijgc-2019-000935
doi: 10.1136/ijgc-2019-000935
doi:

Substances chimiques

Coloring Agents 0
Indocyanine Green IX6J1063HV

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

339-345

Informations de copyright

© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: JP and CL have received honoraria from Intuitive Surgical for proctoring and lectures in robot assisted surgery, and HF has received honoraria from Intuitive Surgical and Medtronics for similar services.

Auteurs

Michele Bollino (M)

Department of Obstetrics and Gynecology, Division of Gynecologic oncology, Skåne University Hospital and Lund University, Faculty of Medicine, Clinical Sciences, Lund, Sweden.

Barbara Geppert (B)

Department of Obstetrics and Gynecology, Division of Gynecologic oncology, Skåne University Hospital and Lund University, Faculty of Medicine, Clinical Sciences, Lund, Sweden.

Celine Lönnerfors (C)

Department of Obstetrics and Gynecology, Division of Gynecologic oncology, Skåne University Hospital and Lund University, Faculty of Medicine, Clinical Sciences, Lund, Sweden.

Henrik Falconer (H)

Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, and Department of Pelvic Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.

Sahar Salehi (S)

Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, and Department of Pelvic Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.

Jan Persson (J)

Department of Obstetrics and Gynecology, Division of Gynecologic oncology, Skåne University Hospital and Lund University, Faculty of Medicine, Clinical Sciences, Lund, Sweden jan.persson@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH